DREAM: a phase 2 trial of Durvalumab with first line chemotherapy in Mesothelioma

What was the trial about?

The standard, proven treatment for advanced mesothelioma is chemotherapy. Treatment with immune checkpoint inhibitors, drugs that activate the body’s immune system to attack some types of cancer, has been shown to improve survival in people with advanced cancers of the lung, kidney, skin, and other organs. DREAM was designed to determine the possible benefits of combining an immune checkpoint inhibitor called durvalumab with standard chemotherapy in people with advanced mesothelioma. All the people who took part in the DREAM trial (participants) were treated with this combination of durvalumab and standard chemotherapy.

What did the trial show?

The trial showed that the combination of durvalumab and standard chemotherapy was safe and had promising effects against mesothelioma. Scans showed control of mesothelioma for 6 months or longer in 31 of the 54 participants in the trial, which was higher than the 25 participants expected with chemotherapy alone.

How will the results help patients and doctors in future?

Following these promising results, our research team is working together with researchers in the USA to open and complete a larger trial that will directly compare the combination standard chemotherapy plus durvalumab versus standard chemotherapy without durvalumab in over 400 people with mesothelioma.